Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer

Bibliography

• Small E, Higano C, Tchekmedyian O, Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer [abstract]. J Clin Oncol (meeting abtracts) 2006;24:4609
   Google Scholar
• Yang JC, Hughes M, Kammula U, Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30(8):825-30
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko IN, Luft A, Phase II trial of ipilimumab and paclitaxel/carboplatin in first-line stage IIIb/IV non-small cell lung cancer [abstract no. 7531]. J Clin Oncol 2010;28(Suppl):208
   Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26
   PubMed Web of Science ®Google Scholar
• Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf
   Google Scholar
• Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995;7(5):682-6
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Hamaoka T. Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state. Immunol Res 1995;14(4):271-91
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006;16:115-23
   PubMed Web of Science ®Google Scholar
• Gabriel EM, Lattime EC. Anti-CTL-associated antigen 4: are regulatory T cells a target? Clin Cancer Res 2007;13(3):785-8
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, CTLA-4 can function as a negative regulator of T c activation. Immunity 1994;1(5):405-13
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3(5):541-7
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271(5256):1734-6
   PubMed Web of Science ®Google Scholar
• Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000;192(2):295-302
   PubMed Web of Science ®Google Scholar
• Perrin PJ, Maldonado JH, Davis TA, CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996;157(4):1333-6
   PubMed Web of Science ®Google Scholar
• Contardi E, Palmisano GL, Tazzari PL, CTLA-4 is constitutively expressed on tumour cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005;117:538-50
   PubMed Web of Science ®Google Scholar
• Grossi F, Salvi S, Merlo F, Evaluation of CTL antigen 4 (CTL-A4) expression as prognostic factor in non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(Suppl):abstract e21157
   Google Scholar
• Small EJ, Tchekmedyian NS, Rini BI, A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13:1810
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15(23):7412-20
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Neyns B, Linette G, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155
   PubMed Web of Science ®Google Scholar
• Hersh EM, O'Day SJ, Powderly J, A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naıve patients with advanced melanoma. Invest New Drugs 2011;29(3):489-98
   PubMed Web of Science ®Google Scholar
• O'Day SJ, Maio M, Chiarion-Sileni V, Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010;21:1712
   PubMed Web of Science ®Google Scholar
• Fong L, Kwek SS, O'Brien S, Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009;69:609
   PubMed Web of Science ®Google Scholar
• Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009;58:823
   PubMed Web of Science ®Google Scholar
• Beck KE, Blansfield JA, Tran KQ, Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283
   PubMed Web of Science ®Google Scholar
• Ridolfi L, Ridolfi R. Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010). Expert Rev Dermatol 2009;4:199
   Google Scholar
• Chin K, Ibrahim R, Berman D, Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA4 therapy [abstr]. Ann Oncol 2008;19(Suppl 8):viii244- 787P
   Google Scholar
• Phan GQ, Weber JS, Sondak VK. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. 25. Ann Surg Oncol 2008;15(11):3014-21
   PubMed Web of Science ®Google Scholar
• Siegel R, Ward E, Brawley O, A cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36
   PubMed Web of Science ®Google Scholar
• Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007;25(Suppl 2):B61-71
   PubMedGoogle Scholar
• Atanackovic D, Altorki NK, Stockert E, Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004;172(5):3289-96
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Zielinski H, Linder A, Final results of a multi-center, double blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small lung cancer (NSCLC). J Clin Oncol 2007;25(18S):abstract 7554
   Google Scholar
• NCT00480025. GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small cell lung cancer (MAGRIT trial). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00480025?term=MAGE-A3&rank=8
   Google Scholar
• Beatson RE, Taylor-Papadimitriou J, Burchell JM. MUC1 immunotherapy. Immunotherapy 2010;2(3):305-27
   PubMed Web of Science ®Google Scholar
• Butts C, Maksymiuk A, Goss C, A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. J Thorac Oncol 2007;2(Suppl 4):S332-3
   Google Scholar
• NCT00409188. Cancer vaccine study for unresectable stage III non-small cell lung cancer (START trial). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00409188?term=00409188&rank=1
   Google Scholar
• NCT 01015443. Cancer vaccine study for stage III, unresectable, non-small cell lung cancer (NSCLC) in the Asian population (INSPIRE trial). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01015443
   Google Scholar
• Quoix E, Ramlau R, Westeel V, Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011;12(12):1125-33
   PubMed Web of Science ®Google Scholar
• Gonzales G, Crombet T, Neninger E, Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin 2007;3(1):8-13
   PubMed Web of Science ®Google Scholar
• Gonzales G, Crombet T, Torres F, Epidermal growth factor-based cancer vaccine for non-small cell lung cancer therapy. Ann Oncol 2003;14(3):461-6
   PubMed Web of Science ®Google Scholar
• Gonzales G, Crombet T, Neninger E, Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 2001;16(1):93-102
   PubMed Web of Science ®Google Scholar
• NCT00516685. Vaccine therapy in treating patients with non-small cell lung cancer (NSCLC) stage IIIB/IV. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00516685?term=EGF+vaccine&rank=1
   Google Scholar
• Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00676507
   Google Scholar
• Stanford JL, Stanford CA, O'Brien ME, Grange JM. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 2008;44(2):224-7
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko IN, Luft A, Ipilimumab in combination with paclitaxel and carboplatin as first line treatment in non-small cell lung cancer: analysis by baseline histology in a phase 2 trial [abstract no. 701]. WCLC; 2011
   Google Scholar
• Reck M, Bondarenko IN, Luft A, Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in extensive disease-small cell lung cancer (ED-SCLC): Results from a phase 2 trial [abstract no. 1365]. WCLC
   Google Scholar
• CT00527735 Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC). Available from: http://clinicaltrials.gov/ct2/show/NCT00527735?term=ipilimumab+lung+neoplasms&rank=2
   Google Scholar
• NCT01331525 The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer (ICE). Available from: http://clinicaltrials.gov/ct2/show/NCT01331525?term=ipilimumab+lung+neoplasms&rank=1
   Google Scholar
• NCT01285609 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin. Available from: http://clinicaltrials.gov/ct2/show/NCT01285609?term=ipilimumab+lung+neoplasms&rank=5
   Google Scholar
• NCT01471197 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01471197?term=ipilimumab+lung+neoplasms&rank=4
   Google Scholar
• Yang A, Kendle RF, Ginsberg BA, CTLA-4 blockade with ipilimumab increases peripheral CD8+T cells: correlation with clinical outcomes. J Clin Oncol 2010;28(Suppl):abstract 2555
   Google Scholar